Site search

Clear filter
2956 results for '' found
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
Staphylococcus aureus Network Adaptive Platform trial (SNAP) (NCT05137119)
/
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
SMITE: Superiority of Migraine Inpatient Treatment with Eptinezumab (ACTRN12621001616864)
/
A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) (NCT02821013)
/
A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in adult participants diagnosed with Schizophrenia (NCT06
/
SODa-BIC: Sodium Bicarbonate For Metabolic Acidosis in the Intensive Care Unit, A Multicentre, Randomised, Double-Blind Clinical Trial (NCT05697770)
/
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera (NCT05499013)
/
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
Switching patients from intravenous to subcutaneous infliximab in inflammatory bowel disease (ACTRN12621001498886)
/
A randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients (NCT05860881)
/
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line
/
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for
/
35 36 37 38 39